TB-500

Mechanism

Evidence tier: 3 — Mechanism characterized in foundational Goldstein 2005 + Malinda 1999 animal-RCT and in-vitro work; human clinical mechanism data is thinner.

TB-500 is a synthetic 17-amino-acid fragment of thymosin β-4 (Tβ4), the dominant G-actin-sequestering peptide in mammalian cells. The fragment includes the active LKKTETQ binding domain that mediates Tβ4's actin interactions. Mechanistically, TB-500 functions upstream of cytoskeletal reorganization — it binds monomeric G-actin and modulates F-actin polymerization, which in turn supports cell migration, angiogenesis, and tissue remodeling. Goldstein 2005 (PMID 16099219) characterized the actin-sequestering biology and the broader "moonlighting" role of Tβ4 in tissue repair. The downstream effects relevant to community use cases — endothelial cell migration into wound beds, fibroblast recruitment, and modulation of inflammatory cytokine signaling — were demonstrated in the Malinda 1999 wound-healing animal work (PMID 10469335) and subsequent cardiac and corneal injury models. TB-500's effect profile is distinct from but complementary to BPC-157's VEGF-driven angiogenic signaling, which is why the two are commonly stacked.

Typical protocols

Evidence tier: 5 — Community-evolved dosing; no completed human RCT has validated the schedule. Documenting what's in use, not endorsing it.

Community protocols typically use a two-phase schedule. Loading phase (weeks 1-4 to 1-6): 2.0-2.5 mg subcutaneously twice weekly, totaling 4-5 mg per week. Maintenance phase (weeks 4-12 or 6-12): 2.0-2.5 mg subcutaneously once weekly. Total cycle length is most commonly 8-12 weeks. Injection is subcutaneous; site rotation between abdomen and thigh is standard. Some protocols site-inject near the indication (e.g., abdominal subcutaneous tissue for systemic effect, periarticular for joint indications) — the evidence base does not clearly support one approach over the other in humans. The dominant use case in 2026 is the BPC-157 + TB-500 stack for post-surgical or tendinopathy recovery — see the full recovery stack walkthrough. Dosing in trial-grade Tβ4 work (RGN-259 corneal eye drops, RGN-352 cardiac IV) used different routes and concentrations and is not directly translatable to subcutaneous community protocols.

Evidence by indication

Evidence tier: 3 — Tendon, cardiac, and corneal models have animal-RCT evidence; human translation is small Phase 1/2 data in adjacent formulations.

Tendon and soft-tissue repair (animal): Multiple rat and rabbit models of Achilles tendon transection and ligament injury show accelerated repair with Tβ4 administration. Cellular-migration and angiogenic mechanisms are consistently demonstrated.

Wound healing (animal + Phase 2 human, related compound): Malinda 1999 (PMID 10469335) established accelerated dermal wound healing in rodents. The full-length Tβ4 product (RGN-137) progressed to Phase 2 in epidermolysis bullosa with mixed signal.

Cardiac repair (animal): Bock-Marquette 2004 demonstrated Tβ4 cardioprotection in murine MI models. RGN-352 (IV Tβ4) entered early human trials in cardiac indications; the program was discontinued for non-efficacy reasons.

Corneal wound healing (Phase 2/3 human, related compound): RGN-259 topical Tβ4 eye drops reached Phase 3 for dry eye and neurotrophic keratitis with mixed primary-endpoint outcomes.

Combination with BPC-157 in soft-tissue recovery: Tier 5 — no RCT data on the combination as a unified protocol. The mechanistic rationale (BPC-157 vascular signaling + TB-500 cytoskeletal/migration) is plausible. The empirical evidence is community-anecdotal.

Cross-link: see the BPC-157 vs TB-500 comparison and the peptides for tendinopathy article for indication-specific positioning.

Safety profile

Evidence tier: 3 — Animal toxicology and limited human Phase 1/2 data with related Tβ4 compounds; long-term human safety data is absent.

TB-500 has a clean profile in animal toxicology studies at therapeutic doses. The most consistent human reports from community use are mild and transient: injection-site erythema, low-grade fatigue or "head fog" in the first 24-72 hours of loading, occasional dizziness. No serious adverse-event signal has emerged in published case series.

The mechanistic concerns that remain theoretical: angiogenesis promotion is a relative contraindication in patients with active or recent malignancy, particularly tumor types where neovascularization drives progression. The actin-sequestering mechanism is broadly distributed across tissue types and the long-term effect on tissues with high mitotic activity is not characterized in chronic human dosing. Patients with active autoimmune disease should discuss with a clinician — the inflammatory modulation is bidirectional. WADA prohibits TB-500 in-competition and out-of-competition; athletes subject to testing should not use it.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning combining mechanism + evidence tier; the closest direct comparator is BPC-157.

The most direct comparator is BPC-157, which has stronger preclinical tendon-healing data and similar animal-RCT evidence quality. TB-500 is preferred over BPC-157 monotherapy when cardiac or broader systemic repair is part of the indication, when the patient has failed a BPC-157-only trial, or when the community-evolved combination protocol is being used. For dermal wound healing, GHK-Cu has more direct human data than TB-500 — see the recovery stack for how the three molecules are typically combined. For tendinopathy specifically, BPC-157 is usually first-line in community practice with TB-500 added in non-responders or surgical-recovery contexts. There is no scenario where TB-500 displaces validated standard-of-care interventions (physical therapy, PRP for selected indications, surgical revision when indicated) — it sits as adjunct, not replacement.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

TB-500 currently sits at Interim FDA Category 2 status pending the PCAC July 23, 2026 meeting that will formally evaluate it for the 503A bulks list. Many 503A compounding pharmacies stopped dispensing during 2024-2025 enforcement actions; a smaller number continue under contested legal theories with documented medical necessity. Telehealth providers with 503A partnerships remain a primary patient-access pathway — see our clinic directory filtered for recovery indications. Research-supplier sourcing is strongly discouraged due to purity and contamination risk plus the regulatory exposure to the patient. WADA-prohibited; athletes should not use it. The July 2026 PCAC decision is the key regulatory inflection point for 2026.

References

• Goldstein AL, Hannappel E, Kleinman HK. 2005. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. PMID 16099219
• Malinda KM, Sidhu GS, Mani H, et al. 1999. Thymosin β4 accelerates wound healing. J Invest Dermatol. PMID 10469335
• Sikiric P, Seiwerth S, Brcic L, et al. 2010. Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Curr Pharm Des. PMID 20388964
• FDA. Pharmacy Compounding Advisory Committee — July 2026 meeting agenda. fda.gov

Limitations

TB-500 should not be used in patients with active or recent malignancy (the angiogenic mechanism is a relative contraindication, particularly for tumor types where neovascularization drives progression), patients on therapeutic anticoagulation without surgical-team review, pregnant or nursing patients, anyone subject to WADA testing, or pediatric patients. Self-sourced research-supplier material is unsuitable for any patient given purity and contamination risk.

The cited evidence cannot tell us whether subcutaneous TB-500 dosing produces effects comparable to the IV Tβ4 used in Phase 1/2 cardiac and corneal trials, what the optimal dose-response relationship is in human soft-tissue repair, or whether the BPC-157 + TB-500 combination outperforms BPC-157 monotherapy in a controlled trial. We would change our framing on the July 2026 PCAC decision, publication of any human RCT of TB-500 in a tendinopathy or post-surgical indication, or completion of a stack-vs-monotherapy comparison.